Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | AOC1 | P19801 | 2/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296322 | 0.71 | MAPK1 (0.35) | KDM4EMEN1USP2ALDH1A1POLB | |
| SCHEMBL27110121 | 0.71 | PSMD14 (0.31) | KDM4EMEN1USP2ALDH1A1POLB | |
| SCHEMBL10273606 | 0.71 | CCR1 (0.34) | HSP90AA1KDM4EMEN1USP2ALDH1A1 | |
| SCHEMBL3246251 | 0.71 | CDC7 (0.35) | KDM4EMEN1USP2ALDH1A1POLB | |
| SCHEMBL1062528 | 0.67 | HSP90AA1 (0.52) | HSP90AA1NCF1KDM4EMEN1ALDH1A1 | |
| SCHEMBL19655732 | 0.67 | — | — | |
| SCHEMBL14154763 | 0.67 | NOS3 (0.34) | — | |
| SCHEMBL15745718 | 0.67 | — | — | |
| SCHEMBL20172095 | 0.67 | HSP90AA1 (0.48) | HSP90AA1KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL12338376 | 0.67 | LMNA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7691858-B2 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259876-A1 | Kinase inhibitors and methods of use thereof | ROCK1, ADCK1, MAP3K20 | HSP90AA1 1884/4885AOC1 2871/4885AOC3 4044/4885 |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | HSP90AA1 1494/4885AOC1 1612/4885AOC3 3445/4885 |
| US-20050282814-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | HSP90AA1 1494/4885AOC1 1612/4885AOC3 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.